U.S. Markets open in 8 hrs 2 mins

Blog Exposure - Portola Pharma Receives Approval from FDA for Its Lead Candidate

Stock Monitor: China Biologic Products Holdings Post Earnings Reporting

LONDON, UK / ACCESSWIRE / May 08, 2018 / If you want access to our free research report on Portola Pharma, Inc. (NASDAQ: PTLA), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=PTLA as the Company's latest news hit the wire. On May 03, 2018, the Company announced that the US Food and Drug Administration (FDA) has approved its lead candidate, Andexxa®, the first and only antidote indicated for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. Register today and get access to over 1,000 Free Research Reports by joining our site below:


Active-Investors.com is currently working on the research report for China Biologic Products Holdings, Inc. (NASDAQ: CBPO), which also belongs to the Healthcare sector as the Company Portola Pharma. Do not miss out and become a member today for free to access this upcoming report at:


Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Portola Pharma most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:


About Andexxa®

Andexxa® is a recombinant protein specifically designed to bind to Factor Xa inhibitors and rapidly reverse their anticoagulant effect. Andexxa® is a modified form of the human Factor Xa molecule, an enzyme that helps blood clot. Andexxa® works by acting as a decoy for oral and injectable Factor Xa inhibitors, which target and bind to Factor Xa, and which allows them to exert their anticoagulant effect.

Importance of Andexxa®

The use of Factor Xa inhibitors is rapidly growing because of their efficacy and safety profile compared to enoxaparin and warfarin in preventing and treating thromboembolic conditions, such as stroke, pulmonary embolism, and venous thromboembolism (VTE). This growth has come with a related increase in the incidence of hospital admissions and deaths related to bleeding, the major complication of anticoagulation. In the US alone in 2016, there were approximately 117,000 hospital admissions attributable to Factor Xa inhibitor-related bleeding, and nearly 2,000 bleeding-related deaths are recorded per month as per the press release.

Andexxa® received both the FDA's Orphan Drug Designation and the Breakthrough Therapy Designation, and was approved under the FDA's Accelerated Approval pathway based on the change from baseline in anti-Factor Xa activity in healthy volunteers. Continued approval for this indication may be contingent upon post-marketing study results to demonstrate an improvement in hemostasis in patients.

Research Results

Andexxa®'s approval was supported by the data from two Phase-3 ANNEXA studies (ANNEXA-R and ANNEXA-A) published in The New England Journal of Medicine, which evaluated the safety and efficacy of Andexxa® in reversing the anticoagulant activity of the Factor Xa inhibitors, rivaroxaban and apixaban, in healthy volunteers. The results demonstrated that Andexxa® rapidly and significantly reversed anti-Factor Xa activity, i.e. the anticoagulant mechanism of these medicines. The median decrease in anti-Factor Xa activity from baseline was 97% for rivaroxaban and 92% for apixaban.

The FDA, as part of its review and approval, also studied data from Portola's ongoing ANNEXA-4 single-arm, open-label study in patients with major bleeding. The data from 185 evaluable patients showed that Andexxa® rapidly and significantly reversed anti-Factor Xa activity when administered as a bolus, and sustained this reversal when followed by a 120-minute infusion. The median decrease from baseline was 90% for rivaroxaban and 93% for apixaban.

The post-marketing requirement for Andexxa® is a clinical trial that randomizes patients to receive either Andexxa® or usual care (the type of care the enrolling institution would provide in the absence of Andexxa®). This study is scheduled to be initiated in 2019, and to be reported in 2023.

Future Plans

Portola is forecasting to launch Andexxa® under an Early Supply Program with Generation 1 product in early June 2018. The broader commercial launch for the products is anticipated in early 2019 upon the FDA's approval of its Generation 2 manufacturing process.

The Marketing Authorization Application (MAA) for andexanet alfa is also under review by the European Medicines Agency. The Committee for Medicinal Products for Human Use (CHMP) communicated a positive trend vote on the MAA in February 2018. A formal opinion from the CHMP is expected by the end of 2018, and the European Commission is expected to issue a decision in early 2019.

Stock Performance Snapshot

May 07, 2018 - At Monday's closing bell, Portola Pharma's stock dropped 3.96%, ending the trading session at $40.76.

Volume traded for the day: 3.99 million shares, which was above the 3-month average volume of 1.42 million shares.

Stock performance in the last month – up 31.87%; and past twelve-month period – up 6.59%

After yesterday's close, Portola Pharma's market cap was at $2.19 billion.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 0.2% at the end of the session.


Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.


For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors